[4]Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020....
2001. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169:27-32.Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell ...
[12]Akamatsu H, Toi Y, Hayashi H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibi...
表皮生长因子受体酪氨 酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)主要通过与酪氨酸激酶域中 的三磷酸腺苷(adenosine triphosphate,ATP)竞争性结合 来抑制 EGFR 的自身磷酸化,进而抑制 EGFR 信号通路 的传导,阻止肿瘤细胞的增殖及转移 .[5―6] 目前根据药 物作用位点及结合...
这是第一项显示抗PD-1抗体加化疗对EGFR突变的NSCLC患者在应用酪氨酸激酶抑制剂治疗后疾病发生了进展的益处的前瞻性3期试验。 SCI 9 May 2023 Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor the...
2. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer, https://doi.org/10.1200/JCO.2016.69.6179. ...
以EGFR和ALK为靶点的小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)在EGFR和ALK基因突变的NSCLC中显示出显著的疗效[7,8]。然而,TKIs在应用过程中会遇到一个共同的问题,即耐药问题。对于EGFR和ALK突变的NSCLC患者,TKIs耐药之后治疗方案的选择是一个难题[9,10]。
其中NSCLC(non-small cell lung cancer,非小细胞肺癌)占所有肺癌比例约80%,表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)对于EGFR阳性突变的非小细胞肺癌患者具有良好的耐受性和抗肿瘤活性[1],并得到了广泛的临床应用。然而,EGFR-TKIs在治疗过程中常发生...
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer Cell Oncol, 36 (2013), pp. 277-288 CrossrefView in ScopusGoogle Scholar 28 M.J. Jameson, L.E. Taniguchi, K.K. VanKoevering, M.M. St...
2.Cho B C, Lee K H, Cho E K, et al. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC...